European HIV
Meeting category
Date(s)
22 May 2024 - 24 May 2024
Program Language
English
Location
Barcelona, Spain
Meeting type
Hybrid Meeting
CME Credits
9
Organizer

European Meeting on HIV & Hepatitis 2024

General
What's New

  • The European Meeting on HIV & Hepatitis 2024 has received COMPLIANT status from Ethical MedTech Europe platform.
     

  • The European Meeting on HIV & Hepatitis 2024 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 9 CME credits (ECMEC®s). For more information, please visit the 'Accreditation' tab.
     

  • The Networking Dinner has been confirmed to be held at the following restaurant:

           Restaurant Abrassame
           Gran Via de les Corts Catalanes, 373, 
           385, L'Eixample, 08015 Barcelona
           Spain

          Distance from the meeting venue: 270 m (4-min walking)

    **The Networking Dinner is not included in the registration fee. Should you wish to attend the Networking Dinner, an additional fee of €65 is charged. Pre-booking is required via the conference secretariat.
     

  • The European Meeting on HIV & Hepatitis 2024 has been submitted to Ethical MedTech Europe platform for compliance.

     
  • The confirmed venue for the European Meeting on HIV & Hepatitis 2024 is at the following location: 

              Hotel Catalonia Barcelona Plaza
              Pl. d'Espanya, 8, Sants-Montjuïc
              08014 Barcelona
              Spain

              Distance from Barcelona Airport (BCN): 13 km

     
  • To stay updated on the latest developments, make sure you are signed up for our newsletter
Welcome

It is our pleasure to confirm that the 22nd Edition of the European Meeting on HIV & Hepatitis will take place as a hybrid meeting on 22-24 May 2024 at Hotel Catalonia Barcelona Plaza in Barcelona, Spain.

Founded more than twenty years ago as the European HIV Resistance Workshop, the European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance has evolved to embrace all aspects of the clinical care of people living with HIV in Europe. This workshop places emphasis in particular on optimal treatment strategies, clinical virology, molecular epidemiology, and public health aspects of HIV, HBV, HCV, as well as emerging viruses throughout Europe.

In the last decade, the meeting has been able to capture leading clinicians and researchers from different regions of Europe. As such, this meeting is the only European platform where HIV-treating physicians and clinical virologists get together on an annual basis to present their latest research results and discuss their clinical implications in detail.

General Information 

Who Should Attend?
Primary: Europe-based clinicians/physicians and researchers involved in the fields of HIV, HBV, and HCV.

Secondary: Laboratory managers, technicians, pharmacists, and pharmacologists.

- Residents, post-graduates, and PhD students

- Government agency personnel, NGO representatives, and health authority personnel

- Industry representatives

- Social workers, advocates, and community workers

- Other healthcare professionals involved in treating HIV and co-infected patients
Meeting Objectives
This meeting aims to:

- Gather professionals in the fields of HIV and hepatitis clinical care and research in an interactive workshop setting;

- Provide a platform for presentation and discussion of the latest developments in the field of antiviral drug development;

- Map important current studies and results;

- Translate new data into treatment guidelines; and

- Educate clinicians on how to best implement current and new drugs in clinical practice.
Learning Objectives
After participating in this activity, participants will be able to:

- Summarize recent results (including clinical trial results) in drug development for HIV or Hepatitis.

- Apply the latest scientific results into daily clinical care to improve the quality of life of individuals living with HIV.

- Identify future challenges in the screening, monitoring and diagnosis of patients living with HIV or Hepatitis and develop new concepts for research and care strategies.

Practical Information 

Ethical MedTech
We are glad to inform that the European Meeting on HIV & Hepatitis 2024 has received COMPLIANT status from Ethical MedTech Europe platform.

For more information, you can visit the website of Ethical MedTech EU with the following link: https://www.ethicalmedtech.eu/
Venue
The confirmed venue for the European Meeting on HIV & Hepatitis 2024 is at the following location:

Hotel Catalonia Barcelona Plaza
Pl. d'Espanya, 8, Sants-Montjuïc
08014 Barcelona
Spain

Distance from Barcelona Airport (BCN): 13 km
Accommodation
To make your experience even more convenient, we have partnered with Hotel Catalonia Barcelona Plaza, the hotel meeting venue, to offer exclusive accommodation rates during the meeting dates.

You can find more information under the "Accommodation" tab on this website.

Please note that Accommodation is not included in the registration fee.
Networking Dinner
Networking Dinner Venue:

Restaurant Abrassame
Gran Via de les Corts Catalanes, 373,
385, L'Eixample, 08015 Barcelona
Spain

Distance from the meeting venue: 270 m (4-min walking)

**The Networking Dinner is not included in the registration fee. Should you wish to attend the Networking Dinner, an additional fee of €65 is charged. Pre-booking is required via the conference secretariat.
Badges
All participants are requested to wear the badge at all times during the conference to ensure admission to the meeting.
Certificate of Attendance
A certificate of attendance will be sent to you after successfully completing the program and post-meeting survey.
Language
The official language of the meeting is English. Translation is not provided.
Conference Materials
The meeting materials can be obtained upon registration at the registration desk at the venue.
Disclaimer
This conference is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this event, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the conference.
Liability and Insurance
By registering for the conference participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Photographs, Audio, and Video Recording
Photographs, audio, and video recordings are not permitted at the official meeting sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted here as soon as possible after the workshop is finished, provided the speaker has given permission to do so.
Code of Conduct
All attendees, speakers, co-organizers, partners, endorsers, suppliers, volunteers, and employees at any of our programs are expected to observe our Code of Conduct. We cannot tolerate any form of discrimination, harassment, disrespect, or the marginalization of those involved in our programs. All participants of VE and AME-organized programs are expected to treat others with dignity and respect at all times.

Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to VE and AME via info@amededu.com or to one of our on-site personnel.
Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.
Program

Please find the preliminary program for the European Meeting on HIV & Hepatitis 2024 below.

Day 1 - Wednesday, 22 May 2024

Opening of the European Meeting on HIV & Hepatitis - 13:30
13:30 CEST
Welcome Coffee
14:00 CEST
Opening Words by the Chairs
Josep Llibre, MD, PhD
Fundació Lluita contra la Sida; Hospital Universitari Germans Trias i Pujol, Spain
Laura Waters, MD, FRCP
Central & North West London NHS Foundation Trust, United Kingdom
Opening Session: HIV Prevention in Europe - State of the Art - 14:05
14:05 CEST
Current Implementation of PrEP in EU: Data from the ECDC
Teymur Noori, MSc
European Centre for Disease Prevention and Control (ECDC), Sweden
14:25 CEST
The Role of Social and Structural Determinants on Access to PrEP
Michael Meulbroek
BCN Checkpoint, Spain
14:45 CEST
Resistance Considerations in Choosing PrEP across Europe
Anna Maria Geretti, MD, PhD, FRCPath
University of Rome, Italy / King's College London, United Kingdom
15:05 CEST
Prevention of STI's: The Role of Doxy-PEP
Deniz Gökengin, MD, PhD
Ege University, School of Medicine, Department of Infectious Diseases, Turkey
15:25 CEST
Panel Discussion: Choosing the Most Suitable PrEP for Each European Setting
15:55 CEST
Coffee Break & Poster Viewing
16:25 CEST
Cardiovascular Interventions in People Living with HIV
16:45 CEST
Weight Gain and ARV Therapy: What a Clinician Needs to Know
Laura Waters, MD, FRCP
Central & North West London NHS Foundation Trust, United Kingdom
17:05 CEST
Charles Boucher Lecture: The Role of bNAbs in Clinical Management of PLWHIV
17:25 CEST
Discussion
17:45 CEST
Networking Reception & Poster Viewing
End of Day 1

Day 2 - Thursday, 23 May 2024

Session 2: What Is New in HIV Treatment - 09:00
09:00 CEST
Personalized Treatment Regimens
Josep Llibre, MD, PhD
Fundació Lluita contra la Sida; Hospital Universitari Germans Trias i Pujol, Spain
09:20 CEST
Women's Health Throughout the Life Cycle
Oana Săndulescu, MD, PhD
Carol Davila University of Medicine and Pharmacy / National Institute for Infectious Diseases "Prof.Dr. Matei Bals", Romania
09:40 CEST
Oral Abstract Presentation #2 - Total HIV DNA and cell-associated HIV RNA viral reservoirs in PBMCs and GALT in patients on triple-ART and switching to dual-ART regimens
Sohaib Khan
University of Rome "Tor Vergata", Italy
09:50 CEST
Oral Abstract Presentation #3 - HIV Reverse Transcriptase M184V mutation induces a better innate immunity recognition
Elisa Teyssou
Institut Pierre Louis d’Epidémiologie et de Santé Publique Virology Department, France
10:00 CEST
Oral Abstract Presentation #4 - Evaluation of post-translational HIV-1 integrase modifications among drug-naïve and HTE MDR individuals: a proof of concept study from PRESTIGIO registry.
Daniele Armenia
Saint Camillus International University of Health Sciences, Italy
10:10 CEST
Oral Abstract Presentation #5 - Clearance of archived Integrase Stand Transfer Inhibitors resistance mutations in virologically suppressed people with HIV
Basma Abdi
AHPH, France
10:20 CEST
Oral Abstract Presentation #6 - The presence of stop codons and/or hypermutation in HIV-1 pol sequences is not associated with the size of reservoir and drives most of APOBEC-context drug resistance mutations
Enagnon Kazali Alidjinou
Uvniversity Hospital of Lille, France
10:30 CEST
Discussion
10:45 CEST
Coffee Break & Poster Viewing
Session 3: HIV & Comorbidities - 11:15
11:15 CEST
Andrea De Luca Lecture Topic: Low Level Viremia: Is It Clinically Relevant?
Annemarie Wensing, MD, PhD
University Medical Center Utrecht, the Netherlands
11:35 CEST
Oral Abstract Presentation #7 - Validation of HIV-1 Drug Resistance Testing by Next Generation Sequencing: Insights from Comparative Long and Short Read Technologies
Martin Daeumer
Institute of Immunology and Genetics, Germany
11:45 CEST
Oral Abstract Presentation #8 - Assessment of integrase resistance mutations in people living with HIV undergoing treatment in Portugal: A two-year (2022-2024) virological failure analysis
Margarida Veloso
Molecular Biology Laboratory, LMCBM, SPC. ULSLO - Hospital Egas Moniz, Portugal
11:55 CEST
Oral Abstract Presentation #9 - Resistance to HIV-1 Integrase strand transfer inhibitors (INSTIs): Cross-sectional observational study carried out in Chile between 2012 and 2023
Pablo Ferrer
Hospital Clinico Universidad De Chile, Chile
12:05 CEST
Oral Abstract Presentation #10 - Role of low-frequency drug-resistant HIV-1 variants on first-line INSTI-containing regimens through Next Generation Sequencing
Maria Mercedes Santoro
University of Rome "Tor Vergata", Italy
12:15 CEST
Oral Abstract Presentation #11 - Distribution of Subtype A Sequence Fragments Among Recombinant Forms of Human Immunodeficiency Virus-1 pol Gene
Karol Serwin
Department Of Infectious, Tropical Diseases And Immune Deficiency Pomeranian Medical University In Szczecin, Poland
12:25 CEST
Oral Abstract Presentation #12 - Increase in HIV-1 transmitted drug resistance and changes in subtype distribution in Estonia
Kristi Huik
University Of Tartu, Estonia
12:35 CEST
Discussion
13:00 CEST
Lunch
Industry-Supported Symposium (non-CME) - 14:00
14:00 CEST
The full program of the "Industry-Supported Symposium" session can be visited in the "Industry Program" Tab when available
15:00 CEST
Coffee Break & Poster Viewing
Session 4: Respiratory Viruses - Update and Relation to People Living with HIV - 15:30
15:30 CEST
Diagnostics on Respiratory Viruses / Multiplex Diagnostics
Carlo Federico Perno, MD, PhD
Pediatric Hospital Bambino Gesù, Italy
15:50 CEST
RSV Immunoprophylaxis: Where Are We and What Is the Impact on Viral Genetic Diversity
Slim Fourati, MD, PhD
Henri Mondor Hospital, Paris-Est University, France
16:10 CEST
The Burden of Respiratory Viruses in Immunocompromised People Living with HIV
Paul Loubet, MD, PhD, MPH
Infectious Diseases Department, Nîmes University Hospital, Montpellier University, France
16:30 CEST
Oral Abstract Presentation #13 - Genomic analysis and circulation pattern of respiratory syncytial virus (RSV) in an Italian pediatric cohort in the season 2022‐2023
Alessia Lai
University Of Milan, Italy
16:40 CEST
Oral Abstract Presentation #14 - Genomic epidemiology of the main SARS-CoV-2 variants circulating in Italy during the Omicron era
Annalisa Bergna
University Of Milan, Italy
16:50 CEST
Oral Abstract Presentation #15 - Divergent SARS-CoV-2-induced immunity signals in the upper and lower respiratory tract in severe COVID-19
Bryan Jimenez Araya
Institut Mondor De Recherche Biomédicale, France
17:00 CEST
Oral Abstract Presentation #16 - RSV viral load and co-infection in a very large cohort of pediatric patients, which role in the disease severity?
Rossana Scutari
Bambino Gesù Children's Hospital, IRCCS, Italy
17:10 CEST
Oral Abstract Presentation #17 - Characterization of long Covid-19 and associated factors in people living with HIV: A systematic review and meta-analysis
Aurelie Minelle Kengni Ngueko
Chantal Biya International Reference Center For Research On Hiv Prevention And Management (CIRCB)), Cameroon
17:20 CEST
Oral Abstract Presentation #18 - ESTIVaRS: Estimation of the Respiratory Syncytial Virus Hospitalization Burden in Older Adults in France
Stephane Marot
APHP, France
17:30 CEST
Discussion
17:45 CEST
End of the Plenary Program
Guided Poster Tours & Networking Dinner - 17:45
17:45 CEST
Guided Poster Tours
End of Day 2
19:30 CEST
Networking Dinner

Day 3 - Friday, 24 May 2024

Session 5: Evolving Challenges in HIV Care - 09:00
09:00 CEST
Migration and Its Impact on the Epidemiology of HIV in Europe
Teymur Noori, MSc
European Centre for Disease Prevention and Control (ECDC), Sweden
09:20 CEST
HIV Care in Migrant Populations
Miłosz Parczewski, MD, PhD
Pomeranian Medical University, Szczecin, Poland
09:40 CEST
Addressing Late HIV Presentation: A Stubborn Unmet Need
Anca Streinu-Cercel, MD, PhD
National Institute of Infectious Diseases "Prof. Dr. Matei Bals", Romania
10:00 CEST
Oral Abstract Presentation #19 - Late Diagnosis: Strategies to overcome the misclassification of individuals with acute infection and low CD4 as Late Presenters
Ana B. Abecasis
Universidade NOVA de Lisboa, Portugal
10:10 CEST
Oral Abstract Presentation #20 - Genomic surveillance of HIV infection in the North Caucasus Federal District of the Russian Federation
Alina Kirichenko
Central Research Institute of Epidemiology, Russian Federation
10:20 CEST
Oral Abstract Presentation #21 - Updates on the clinical epidemiology of HIV-1 group O strains in Cameroon and potential implications on diagnosis and treatment strategies
Collinis Ambe Chenwi
Chantal Biya International Reference Center for Research on HIV and AIDS Prevention and Management (CIRCB), Cameroon
10:30 CEST
Debate: Clinical Value of Proviral DNA Resistance Testing
Francesca Ceccherini-Silberstein, PhD
University of Rome “Tor Vergata”, Italy
Anne-Geneviève Marcelin, MD
Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France
11:10 CEST
Coffee Break & Poster Viewing
Session 6: What's in the Pipeline? Presentations on Future Viral Therapeutics and Vaccines from Scientists from Industry (non-CME) - 11:40
11:40 CEST
The full program of "Session 6: What is in the Pipeline?" can be visited in the "Industry Program" Tab when available
13:00 CEST
Lunch
Session 7: Viral Hepatitis - What’s New in Prevention and Treatment (HBV, HCV, HDV) - 14:00
14:00 CEST
Innovative Diagnostic Strategies and Markers in HBV and HDV
Federico García, PharmD, PhD
Hospital Universitario San Cecilio, Spain
14:20 CEST
New Drugs for HBV & HDV: State of the Art
Heiner Wedemeyer, MD
Hannover Medical School, Germany
14:40 CEST
Acute HCV and Reinfection
Loreta Kondili, MD, PhD
Istituto Superiore Di Sanita, Italy
15:00 CEST
Oral Abstract Presentation #22 - HBsAg production from integrated HBV-DNA sustains HDV persistence in the setting of a limited or even absent HBV reservoir
Stefano D'Anna
University of Rome "Tor Vergata", Italy
15:10 CEST
Oral Abstract Presentation #23 - Different diagnostic performances of HDV RNA quantification assays used in clinical practice in Italy: results from a national quality control multicenter study
Lorenzo Piermatteo
University of Rome "Tor Vergata", Italy
15:20 CEST
Oral Abstract Presentation #24 - Enabling access to HCV care through community-based programming during the active war period for the people living with HIV in Ukraine
Zahedul Islam
Alliance for Public Health, Ukraine
15:30 CEST
Discussion
Closing Session - 15:45
15:45 CEST
Ricardo Camacho Award & Closing Remarks
16:00 CEST
End of the Meeting
Industry Program

Day 2 - Thursday, 23 May 2024

Satellite Symposium ViiV Healthcare - 14:00
14:00 CEST
Welcome and Introduction
Anne-Geneviève Marcelin, MD
Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France
14:05 CEST
Oral 2DRs and Robustness in HIV Treatment
Moderator:
Anne-Geneviève Marcelin, MD
Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France
Speaker:
Federico García, PharmD, PhD
Hospital Universitario San Cecilio, Spain
14:25 CEST
The Effectiveness of LA ART in Clinical Care
Moderator:
Josep Llibre, MD, PhD
Fundació Lluita contra la Sida; Hospital Universitari Germans Trias i Pujol, Spain
Speaker:
Chloe Orkin, MBChB, FRCP, MD
Queen Mary University of London, United Kingdom
14:45 CEST
Panel Discussion and Q&A
14:55 CEST
Summary and Close
Josep Llibre, MD, PhD
Fundació Lluita contra la Sida; Hospital Universitari Germans Trias i Pujol, Spain

Day 3 - Friday, 24 May 2024

Session 6: What's in the Pipeline? Presentations on Future Viral Therapeutics and Vaccines from Scientists from Industry -
Session Chair
Jonathan Schapiro, MD
National Hemophilia Center, Sheba Medical Center, Israel
11:40 CEST
Gilead Sciences
Calvin Cohen, MD, MSc
Executive Director, Global HIV Medical Affairs, Gilead Sciences, United States
12:00 CEST
ViiV Healthcare
Harmony Garges, MD, MPH
Senior Vice President, Chief Medical Officer and Head of Global Medical, ViiV Healthcare, United States
12:20 CEST
Merck-MSD
Rafael Eduardo Campo, MD
MSD, United States
12:40 CEST
Discussion
13:00 CEST
Lunch
Registration

Registration is open.

Fees and Conditions

Regular Delegate
In-Person

Regular Delegate
Virtual


Industry
In-Person
 

Industry
Virtual

Early Fee
(payment before/on 22 October 2023)

€495.00

€395.00

€695.00

€595.00

Standard Fee
(payment before/on 21 May 2024)

€695.00

€595.00

€895.00

€795.00

Same Day Fee
(payment from 22 May 2024)     

€795.00

€695.00

€995.00

€895.00

Discounts

Early-Career Investigators / Regular Delegates from Resource-Limited Settings (RLS)** WITH accepted abstract

Fees Waived 

Early-Career Investigators / Regular Delegates from Resource-Limited Settings (RLS)** WITHOUT accepted abstract

50% Off Current Regular Delegate Fee


People Living with HIV or Hepatitis
 

Fees Waived

(Please contact the Conference Secretariat for a discount code)


Locals / People Living in Spain (In-Person Participation)
 

€75 for students and €250 for HCPs living in Spain

(Please contact the Conference Secretariat for a discount code)

NGO Representatives / Government Representatives (i.e. MOH, NIH, NIAID, etc.) / Advocates

50% Off Current Regular Delegate Fee

Members of Endorsers

25% Off Current Regular Delegate Fee

Sponsors

Contact Secretariat

*Industry representatives may receive a discount based on the level of support provided to the event. For more support and registration information, please contact Jesper.Niesen@amededu.com.

Important
  • We strongly advise that you register early to ensure your registration. Registration will close when the capacity of the venue is reached.

  • Submission of your online registration does not guarantee that your registration has been accepted. Your registration is final when full prepayment has been received and a confirmation of your registration has been sent.

Registration Fee Includes
For onsite attendees:
- Access to all scientific sessions, including poster area;
- Conference pack, including digital abstract book and printed program book;
- Refreshments during the coffee breaks;
- Buffet lunch on meeting days;
- Complimentary entrance to the Networking Reception*
- Access to all enduring materials

* The Networking Reception will take place in the same venue of the meeting and will not have any music / entertainment of any shape or form. The Networking Reception only offers finger foods and the opportunity to have a look at the chosen abstract poster presentations.

For virtual attendees only:
- Access to all scientific sessions
- Digital meeting pack, including the digital abstract book and program book
- Access to all enduring materials

IMPORTANT:

- No day rate is available

- The Networking Dinner is not included in the registration fee. Should you wish to attend the Networking Dinner, an additional fee of €65 is charged. Pre-booking is required via the conference secretariat.

- Virology Education reserves the right to cancel improper registrations. Claims for a refund will not be honored.
Group Registration
For registration of groups larger than 5 participants, please contact Michelle.Wu@amededu.com.
Early-Career Investigators / Regular Delegates from Resource-limited Settings (RLS)
We are pleased to waive the registration fee for early-career investigators and regular delegates from low-income and lower-middle-income countries with an accepted abstract and a 50% discount on the registration fee without an accepted abstract.

IMPORTANT: Complimentary registration is offered to the presenting author only.

To be eligible as an early-career investigator, one should either be - A current Master/PhD student OR
- Have obtained an MD/PharmD/PhD degree in the last five years.

An application form needs to be completed by a supervisor and received by the Virology Education secretariat at least two weeks prior to the start of the workshop. Virology Education will contact the early-career investigator with instructions regarding the registration procedure.
Sponsored Attendance
If you are invited by a pharmaceutical or diagnostic company, or if your registration is organized by a travel agency, please do not register online. The sponsoring company will be asked to register you via the conference secretariat.
Payment
By credit card only: online or by written authorization (see online registration).

Please contact the Secretariat at Michelle.Wu@amededu.com if you need to make alternative arrangements.
Cancellation Policy
In case of cancellation, the following refunds are applicable:

- Cancellation before/on 26 April 2024: 50% refund (minus an administration fee of €40)

- Cancellation after 26 April 2024: Unfortunately, no refund will be given

If you are unable to attend the conference, a substitute delegate is always welcome at no extra charge, provided that a letter of authorization from the original participant has been received and the conference secretariat has been notified of the name of the substitute delegate before 8 May 2024. A statement (email/letter) of cancellation must be sent to Virology Education.
Liability and Insurance
By registering for the conference, participants agree that the organizers do not accept responsibility for medical, travel, or personal insurance. Participants are advised to take out their own insurance policies.
Media Registration
In order to register as a media participant for the workshop, the conference secretariat needs to receive:

1. Proof of accreditation
2. Valid identification (e.g., passport)
3. A letter from your assignment giver stating the details of your assignment (e.g., editor)
4. At least 3 previous written assignments in recognized outlets on HIV. If you are a freelance journalist, the assignments can be from different (recognizable) news outlets. Links to online publications are accepted
5. The website of the publication(s)/blog(s) that will be featuring your story on this workshop

A discounted registration fee may apply for accredited media participants depending on availability. Preference will be given to credible print and online news sources. Please contact the conference secretariat for registration conditions.

We would like to receive a copy of your workshop report/ article once it is finalized.
All credentials will be verified by the Organizing Committee of the Workshop. Media representatives are kindly requested to register by sending the above-mentioned information to info@amededu.com.

Important: Media is restricted to the written press. Recording on film or photo is not allowed. Virology Education will request a copy of the written piece once it is finalized. Media representatives must also agree to abide by the 2024 embargo policy.
Disclaimer
This workshop is intended for educational purposes only and aims to offer participants the opportunity to share information. The organizing secretariat of this workshop, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this workshop. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the workshop. In case of cancellation of the meeting due to unforeseen circumstances, Virology Education cannot be held responsible for expenses made for travel, accommodation, visa applications, etc.
Abstracts
  • The European Meeting on HIV & Hepatitis 2024 accepts new original data as well as encored abstracts. All abstracts must focus on the European region and contain up-to-date information at the time of the meeting. 

  • Complimentary registration is given to early-career investigators with an accepted abstract. A 50% discount is offered to early-career professionals without an accepted abstract. The requirements for the application are specified under the "Registration" tab.

  • Abstract submitters are encouraged to use person-first language in their abstracts. View our guidelines here

Categories for Abstract Submission
For purposes of review and programming, abstracts are divided into topical categories. The selection of the most appropriate category is important as it determines who reviews your abstract. The Organizing Committee reserves the right to reassign your abstract to a more appropriate category.

Abstract Categories:
- Clinical Case
- Clinical Research on HIV and Co-Infections
- Clinical Implications of Antiviral Drug Resistance (Hepatitis B, Hepatitis C and HIV)
- Management of COVID-19 and Other Respiratory Viruses
- HIV Inflammation and Cure
- HIV Prevention, Strategies and Implementation
- Mechanism of Antiviral Drug Resistance (Hepatitis B, Hepatitis C and HIV)
- Novel Diagnostic Technologies & Approaches
- Resistance to Antiviral Drugs (Hepatitis B, Hepatitis C and HIV)
- Spread of Drug Resistance
- Therapeutic Challenges in Resource-Limited Settings
- Treatment Strategies for People Living with HIV / Hepatitis
- Viral Evolution & Genetic Diversity
General Guidelines
Abstracts should contain the following four components:

- Background: A concise statement of the issue under investigation or a hypothesis;

- Material and Methods: The experimental methods used (including the statistical analyses employed);

- Results: Specific findings (promises such as "to be completed" or "to be presented" are not acceptable);

- Conclusions: A summary of findings that are supported by your results (statistical analyses used to support the conclusions, where appropriate, should be included; concluding statements such as "the results will be discussed" are not acceptable).

Please note that abstracts cannot be accepted if tables or graphs are included. The maximum word count for the abstract body is 500 words.

Abstracts are considered official communications to the conference and will be treated confidentially. Submitters of accepted abstracts agree to attend the meeting and present their abstract as scheduled.

We encourage you to use person-first language in your abstract(s). View our guidelines here: https://academicmedicaleducation.com/person-first-language
Abstract Submission
Authors can submit their abstracts electronically until the deadline. You will be redirected to the submission website. Please follow the step-by-step directions to upload the abstract. To ensure your abstract retains any special characters or formatting, the abstract must be in Microsoft Word format.
Poster Presentation Instructions
- You are requested to bring a physical print of your poster to the meeting.
- The measurements of the physical poster should be A0 size (approx 33" x 47"), posted in portrait format.
- Please refrain from printing your poster on textile/fabric, as it will not be able to stick well to the poster boards.
- Please hang your posters as early as possible. Your poster should also be displayed during all meeting days.
- You shall be present at your poster during the poster viewing session in the program.
- Adhesive material (pushpins, velcro, or double-sided tape) for your poster will be provided by the conference secretariat.
Committees
Program Chairs
Organizing Committee

The members of the Organizing Committee are a group of carefully selected experts and inspirational leaders in their respective fields. They meet frequently to discuss the scientific program of the workshop, identify interesting topics and candidate speakers, and review all submitted abstracts.

Scientific Committee

The members of Scientific Committee are hand-picked by the Organizing Committee and the conference secretariat based on their significant contributions and commitment to the field. They assist the Organizing Committee by providing them with suggestions for speakers and topics. In addition, they participate in reviewing submitted abstracts, and play an active role during the workshop as moderators and/or chairs of sessions. 

  • Ana B. Abecasis, MD, PhD, PharmD - Global Health and Tropical Medicine, Institute of Hygiene and Tropical Medicine, Universidade NOVA de Lisboa, Portugal

  • Marina Bobkova, PhD - Ivanovsky Institute of Virology, Russia

  • Stéphane Chevaliez, PharmD, PhD - University of Paris-Est Creteil, France

  • Federico García, PharmD, PhD - Hospital Universitario San Cecilio, Spain

  • Rolf Kaiser, PhD - University of Cologne, Germany

  • Leon Kostrikis, PhD - University of Cyprus, Cyprus

  • Clive Loveday, PhD - ICVC Charitable Trust, Clinical Virology, United Kingdom

  • Anne-Geneviève Marcelin, MD - Hôpital Pitié-Salpétrière Paris, France

  • Monique Nijhuis, PhD - University Medical Centre Utrecht, the Netherlands

  • Roger Paredes, MD, PhD - IrsiCaixa AIDS Research Institute, Spain

  • Mario Poljak, MD, PhD - Institute for Microbiology and Immunology, Slovenia

  • Gary Rubin, MD - University of Toronto, Canada

  • Anne–Mieke Vandamme, PhD - University of Leuven, Belgium

  • Maria Santoro, MD - University of Rome "Tor Vergata", Italy
  • Anders Sönnerborg, MD, PhD - Karolinska Institute, Sweden

  • Janusz Stanczak, PhD - University of Warsaw, Poland

  • Jens Verheyen, MD, PhD - Institute of Immunology and Genetics, Germany

  • David van de Vijver, PharmD, PhD - Erasmus University Rotterdam, the Netherlands

  • Hauke Walter, MD - Medizinisches Labor Stendhal, Germany

  • Annemarie Wensing, MD, PhD - University Medical Center Utrecht, the Netherlands

  • Maurizio Zazzi, PhD - University of Siena, Italy

Accreditation
EACCME® Accreditation Statement

European Meeting on HIV & Hepatitis 2024, Barcelona, Spain, 22/05/2024 - 24/05/2024 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 9 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credits to AMA credits can be found at https://edhub.ama-assn.org/pages/applications.

Live educational activities occurring outside of Canada, recognized by the UEMS-EACCME® for ECMEC® credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Endorsers
Support
Platinum Level

Support provided by ViiV Healthcare.

Silver Level

Supported by Gilead who provided funding. Gilead has had no input into the content of the materials used at this meeting.

Support Our Initiative

Financial backing to the European Meeting on HIV & Hepatitis 2024 helps us deliver an impactful meeting experience to the benefit of healthcare professionals and researchers interested in HIV & Hepatitis in the European region.
 
This collaboration plays a vital role in both the organizational as well as scientific success of the program.

To show your commitment to the cause, get in touch with us for a tailored support package by contacting Jesper Niesen at Jesper.Niesen@amededu.com or call +31 30 230 7140.
 
Benefits of Support
By supporting this program, we can offer the following advantages for your company.* Please contact us for the most recent support level benefits for this program.

  • Symposium opportunities
  • Non-commercial interviews with company representatives
  • Verbal acknowledgement during the program 
  • Discounted and complimentary registrations for your representatives
  • Company acknowledgement on digital meeting materials including but not limited to newsletters, flyers, the streaming platform, and our website
  • Company acknowledgement on printed meeting materials including but not limited to banners and the program book
  • Digital and printed advertising opportunities 
  • Social media shout-outs
  • Logo on the conference bag 

 
*Subject to the support level.

Accommodation
We look forward to welcoming you to Barcelona, Spain!

To make your experience even more convenient, we have partnered with Hotel Catalonia Barcelona Plaza, the hotel meeting venue, to offer exclusive accommodation rates during the meeting dates.

As a valued meeting delegate, you have the opportunity to enjoy reduced rates for your stay during the meeting. We understand the importance of a comfortable and seamless experience, and this special offer is designed to enhance your stay.

If you are interested in this offer, please visit the registration page of the meeting where you will have the opportunity to fill in your accommodation needs in the provided fields. Please note that the special accommodation rates are subject to availability, so we encourage you to secure your registration and hotel reservation early to guarantee your stay at these exclusive rates.

Should you also be interested in having your accommodation arranged by the Organizers directly, please do not hesitate to reach out to us at Michelle.Wu@amededu.com. We will be happy to assist you further, depending on the availability of the hotel.

Media
Invitation to Join the Meeting!

The Program Chair, Dr. Josep Llibre invites you to join the European Meeting on HIV & Hepatitis 2024 from 22 - 24 May 2024 in Barcelona, Spain.

Previous Editions
Language
Ratings previous edition
Content was presented clearly
4.6
Increased my knowledge as healthcare professional
4.5
Overall conference experience
4.6